Vaborbactam

Vaborbactam
Clinical data
ATC code	None;
Identifiers
	IUPAC name {(3R,6S)-2-Hydroxy-3-[2-(thiophen-2-yl)acetamido]-; 1,2-oxaborinan-6-yl}acetic acid;
CAS Number	1360457-46-0;
PubChem CID	56649692;
DrugBank	DB12107;
ChemSpider	35035409;
UNII	1C75676F8V;
KEGG	D10998;
CompTox Dashboard (EPA)	DTXSID901027690 ;
ECHA InfoCard	100.235.136
Chemical and physical data
Formula	C12H16BNO5S
Molar mass	297.13 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES B1([C@H](CC[C@H](O1)CC(=O)O)NC(=O)CC2=CC=CS2)O;
	InChI InChI=1S/C12H16BNO5S/c15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t8-,10-/m0/s1; Key:IOOWNWLVCOUUEX-WPRPVWTQSA-N;

Vaborbactam (INN) is a non-β-lactam β-lactamase inhibitor discovered by Rempex Pharmaceuticals, a subsidiary of The Medicines Company. While not effective as an antibiotic by itself, it restores potency to existing antibiotics by inhibiting the β-lactamase enzymes that would otherwise degrade them. When combined with an appropriate antibiotic it can be used for the treatment of gram-negative bacterial infections.

In the United States, the combination drug meropenem/vaborbactam (Vabomere) is approved by the Food and Drug Administration for complicated urinary tract infections and pyelonephritis. The combination was approved for medical use in Canada in December 2024.

Clinical data

ATC code	None
Identifiers
IUPAC name {(3R,6S)-2-Hydroxy-3-[2-(thiophen-2-yl)acetamido]- 1,2-oxaborinan-6-yl}acetic acid
CAS Number	1360457-46-0
PubChem CID	56649692
DrugBank	DB12107
ChemSpider	35035409
UNII	1C75676F8V
KEGG	D10998
CompTox Dashboard (EPA)	DTXSID901027690
ECHA InfoCard	100.235.136
Chemical and physical data
Formula	C₁₂H₁₆BNO₅S
Molar mass	297.13 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES B1([C@H](CC[C@H](O1)CC(=O)O)NC(=O)CC2=CC=CS2)O
InChI InChI=1S/C12H16BNO5S/c15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t8-,10-/m0/s1 Key:IOOWNWLVCOUUEX-WPRPVWTQSA-N